Current and future treatments of spinal muscular atrophy
- PMID: 31879942
- DOI: 10.1111/dmcn.14447
Current and future treatments of spinal muscular atrophy
Comment on
-
Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.Dev Med Child Neurol. 2020 Mar;62(3):310-314. doi: 10.1111/dmcn.14412. Epub 2019 Dec 4. Dev Med Child Neurol. 2020. PMID: 31799720
References
-
- Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol 2019; 61: 19-24.
-
- Aragon-Gawinska K, Daron A, Ulinici A, et al. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol 2020; 62: 310-4.
-
- Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 62: 310-4.
-
- Boardman FK, Young PJ, Griffiths FE. Newborn screening for spinal muscular atrophy: The views of affected families and adults. Am J Med Genet 2017; 173A: 1546-61.
-
- Boardman FK, Sadler C, Young PJ. Newborn genetic screening for spinal muscular atrophy in the UK: The views of the general population. Mol Genet Genomic Med 2018; 6: 99-108.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
